Opartkiattikul, NTatsumi, NFunahara, YShirahata, AWongtiraporn, WTientadakul, PFucharoen, S2009-05-272009-05-271999-12-05Opartkiattikul N, Tatsumi N, Funahara Y, Shirahata A, Wongtiraporn W, Tientadakul P, Fucharoen S. Hemostatic alterations in beta-thalassemia/hemoglobin E patients. The Southeast Asian Journal of Tropical Medicine and Public Health. 1999 ; 30 Suppl 3(): 86-9http://imsear.searo.who.int/handle/123456789/34622The Southeast Asian Journal of Tropical Medicine and Public Health.To search for evidence of coagulation activation ex vivo, the levels of human prothrombin fragment 1+2 (F1+2) were examined in 69 beta-thalassemia/Hb E patients. Levels of protein C inhibitor (PCI) and activated protein C - PCI (APC:PCI) complex were also determined in 9 of the above patients in conjunction with protein C (PC) antigen and activity, in an attempt to detect increased consumption of PC. In mean level of F1+2, there was a statistically significant difference between normal control and post-splenectomized patients (p < 0.05) but not between normal control and non-splenectomized patients (p > 0.05). The mean levels of PC activity and PC antigen in the patients were much lower than in normal controls. However, the mean levels of PCI and the mean level of APC:PCI complex in the patients were not significantly different from those in normal controls (p > 0.05). The high level of F1+2 in post-splenectomized patients found in this study agreed well with clinical and other laboratory findings. The normal level of PC inhibitor and APC:PCI complex found in this study provided no evidence of increased consumption of protein C in thalassemia patients.engAdultBlood Coagulation Disorders --bloodCase-Control StudiesFemaleHemoglobin EHemoglobinopathies --bloodHumansJapanMalePeptide Fragments --bloodProtein C --antagonists & inhibitorsProthrombin --metabolismSplenectomybeta-Thalassemia --bloodJournal Article